Vivek Subbiah Selected Research

pralsetinib

1/2022	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.
10/2021	Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.
6/2021	The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
1/2021	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
1/2021	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
10/2020	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
10/2020	State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
1/2018	Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vivek Subbiah Research Topics

Disease

177	Neoplasms (Cancer) 04/2022 - 07/2007
24	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 03/2010
22	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 07/2015
18	Disease Progression 01/2022 - 09/2008
16	Melanoma (Melanoma, Malignant) 02/2022 - 01/2010
15	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2011
11	Ewing Sarcoma (Sarcoma, Ewing) 01/2022 - 04/2009
10	Osteosarcoma (Osteogenic Sarcoma) 10/2021 - 07/2011
9	medullary Thyroid cancer 01/2022 - 02/2015
9	Thrombocytopenia (Thrombopenia) 01/2022 - 06/2015
8	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 12/2014
8	Diarrhea 01/2022 - 05/2012
7	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2014
7	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 01/2017
6	Cholangiocarcinoma 02/2022 - 01/2013
6	Nausea 10/2021 - 05/2012
5	Lung Neoplasms (Lung Cancer) 02/2022 - 10/2019
5	Neutropenia 10/2021 - 06/2015
5	Vomiting 10/2021 - 05/2012
5	Exanthema (Rash) 01/2021 - 01/2017
5	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2014
5	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 11/2007
5	Hypertension (High Blood Pressure) 01/2020 - 01/2017
5	Fatigue 01/2019 - 10/2016
5	Desmoplastic Small Round Cell Tumor 10/2018 - 04/2011
4	Carcinoma (Carcinomatosis) 01/2022 - 03/2020
4	Anaplastic Thyroid Carcinoma 01/2022 - 08/2015
4	Renal Cell Carcinoma (Grawitz Tumor) 11/2020 - 02/2015
4	Anemia 11/2018 - 10/2016
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 02/2022 - 01/2020
3	Microsatellite Instability 01/2022 - 01/2019
3	Carcinogenesis 10/2021 - 08/2019
3	Leiomyosarcoma 10/2021 - 12/2016
3	Ovarian Neoplasms (Ovarian Cancer) 10/2021 - 08/2015
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2020 - 01/2020
3	Brain Neoplasms (Brain Tumor) 01/2020 - 07/2015
3	Adenocarcinoma 07/2018 - 07/2015

Drug/Important Bio-Agent (IBA)

14	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2022 - 01/2014
14	Pharmaceutical PreparationsIBA 01/2022 - 09/2014
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 08/2014
12	selpercatinibIBA 01/2022 - 01/2020
11	VemurafenibIBA 02/2022 - 08/2015
11	pazopanib FDA Link 01/2021 - 06/2015
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 06/2015
9	trametinibIBA 02/2022 - 01/2017
9	pembrolizumabIBA 01/2022 - 01/2019
9	Phosphotransferases (Kinase)IBA 01/2022 - 07/2011
8	pralsetinibIBA 01/2022 - 01/2018
8	vandetanib (ZD6474)IBA 01/2021 - 02/2015
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
8	Everolimus FDA Link 01/2021 - 06/2015
8	DNA (Deoxyribonucleic Acid)IBA 03/2020 - 06/2015
8	TOR Serine-Threonine KinasesIBA 01/2018 - 08/2010
7	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2016
6	CrizotinibIBA 10/2021 - 07/2011
6	Immune Checkpoint InhibitorsIBA 01/2021 - 12/2017
6	Bevacizumab (Avastin)FDA Link 01/2020 - 04/2016
6	Proteins (Proteins, Gene)FDA Link 09/2018 - 01/2011
5	Circulating Tumor DNAIBA 01/2022 - 10/2019
5	dabrafenibIBA 01/2022 - 01/2018
5	Radium-223IBA 10/2021 - 01/2014
5	Cetuximab (Erbitux)FDA Link 01/2020 - 08/2015
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 08/2014
4	selinexorIBA 04/2022 - 01/2021
4	PM 01183IBA 01/2022 - 01/2020
4	Biological ProductsIBA 01/2022 - 06/2013
4	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2014
4	PlatinumIBA 11/2021 - 08/2014
4	RadiopharmaceuticalsIBA 10/2021 - 01/2014
4	IpilimumabIBA 01/2021 - 01/2017
4	Gemcitabine FDA Link 01/2021 - 01/2018
4	cabozantinibIBA 01/2021 - 01/2020
4	Vorinostat FDA Link 11/2020 - 10/2016
3	AntibodiesIBA 01/2022 - 07/2011
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 04/2017
3	ceritinibIBA 10/2021 - 03/2016
3	RadiumIBA 10/2021 - 05/2015
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2021 - 01/2016
3	Hormones (Hormone)IBA 01/2021 - 01/2014
3	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2018
3	Histone Deacetylase InhibitorsIBA 11/2020 - 10/2016
3	alovudineIBA 01/2020 - 04/2017
3	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 11/2015
3	CreatinineIBA 01/2019 - 04/2008
3	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 03/2010
3	temsirolimus FDA Link 04/2016 - 01/2014
3	ParaffinIBA 01/2016 - 04/2014
3	Formaldehyde (Formol)FDA Link 01/2016 - 04/2014
2	Topotecan (Hycamtin)FDA LinkGeneric 04/2022 - 10/2021
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 12/2016
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 03/2020

Therapy/Procedure

121	Therapeutics 01/2022 - 07/2007
30	Drug Therapy (Chemotherapy) 01/2022 - 11/2007
23	Immunotherapy 01/2022 - 12/2017
8	Precision Medicine 12/2021 - 03/2014
5	Radiotherapy 01/2022 - 05/2012
4	Time-to-Treatment 10/2021 - 10/2016
4	Investigational Therapies (Experimental Therapy) 01/2021 - 04/2009
3	Castration 01/2021 - 01/2014
3	Neoadjuvant Therapy 10/2018 - 03/2010